We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein (HSIC) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Henry Schein (HSIC - Free Report) closed at $80.90 in the latest trading session, marking a +1.2% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.45%. Meanwhile, the Dow gained 0.8%, and the Nasdaq, a tech-heavy index, added 1.99%.
Coming into today, shares of the health care products maker had gained 8.17% in the past month. In that same time, the Medical sector gained 2.16%, while the S&P 500 gained 4.25%.
Wall Street will be looking for positivity from Henry Schein as it approaches its next earnings report date. On that day, Henry Schein is projected to report earnings of $1.25 per share, which would represent year-over-year growth of 7.76%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.11 billion, up 2.7% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.26 per share and revenue of $12.83 billion, which would represent changes of +9.36% and +1.45%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Henry Schein. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Henry Schein is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Henry Schein is currently trading at a Forward P/E ratio of 15.21. Its industry sports an average Forward P/E of 21, so we one might conclude that Henry Schein is trading at a discount comparatively.
Also, we should mention that HSIC has a PEG ratio of 2.25. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Dental Supplies industry currently had an average PEG ratio of 2.11 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 57, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Henry Schein (HSIC) Outpaces Stock Market Gains: What You Should Know
Henry Schein (HSIC - Free Report) closed at $80.90 in the latest trading session, marking a +1.2% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.45%. Meanwhile, the Dow gained 0.8%, and the Nasdaq, a tech-heavy index, added 1.99%.
Coming into today, shares of the health care products maker had gained 8.17% in the past month. In that same time, the Medical sector gained 2.16%, while the S&P 500 gained 4.25%.
Wall Street will be looking for positivity from Henry Schein as it approaches its next earnings report date. On that day, Henry Schein is projected to report earnings of $1.25 per share, which would represent year-over-year growth of 7.76%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.11 billion, up 2.7% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.26 per share and revenue of $12.83 billion, which would represent changes of +9.36% and +1.45%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Henry Schein. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Henry Schein is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Henry Schein is currently trading at a Forward P/E ratio of 15.21. Its industry sports an average Forward P/E of 21, so we one might conclude that Henry Schein is trading at a discount comparatively.
Also, we should mention that HSIC has a PEG ratio of 2.25. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Dental Supplies industry currently had an average PEG ratio of 2.11 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 57, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.